TABLE 4.

Clinical performance of the three commercial kits in detecting macrolide resistance among 154 specimens with M. genitalium positivity as detected by the three commercial kits and 23S rRNA sequencing data

Commercial kit	23S rRNA mutation	23S rRNA sequencing		% sensitivity (95% CI)	% specificity (95% CI)
		No. mutated	No. WTa
S-DiaMGRes Diagenode	Present	80	2	100 (95.4–100)	97.3 (90.7–99.3)
	Absent	0	72
RealAccurate TVMGres Pathofinder	Present	76	2	95.0 (87.8–98.0)	97.3 (90.7–99.3)
	Absent	4	72
ResistancePlus MG SpeeDx	Present	80	4	100 (95.4–100)	94.6 (86.9–97.9)
	Absent	0	70

^aWT, wild type.